Diet boosts IBD drug power? new study tests food as medicine

NCT ID NCT06896305

Recruiting now Disease control Sponsor: IRCCS Ospedale San Raffaele Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding a special diet called the Crohn's Disease Exclusion Diet (CDED) to standard anti-TNF therapy can improve outcomes for people with active Crohn's disease or ulcerative colitis. Eighty adults starting anti-TNF drugs will be randomly assigned to either receive dietary advice on CDED or continue with medication alone. The goal is to see if the diet helps more patients achieve symptom remission and better quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Crohn's Disease Exclusion Diet (CDED) plus anti-TNF therapy
What this could lead to: If it works, this could show that a specific diet helps anti-TNF drugs work better for people with inflammatory bowel disease, potentially improving symptom control and quality of life.
What could go wrong: This is a small, early-stage study with only 80 participants. Diet adherence is voluntary and not enforced, so results may vary. The diet is restrictive and may be hard to follow long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE (CD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHN DISEASE (CD) ULCERATIVE COLITIS (UC)

Contacts and locations

Locations

IRCCS Ospedale San Raffaele
RECRUITING

Milan, Michigan, 20132, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.